Collegium to acquire ADHD drug Azstarys

Collegium Pharmaceutical is set to acquire the ADHD medication Azstarys from Corium for a potential $785 million. This strategic acquisition includes an upfront payment of $115 million, with additional milestone payments contingent on future performance. The deal aims to bolster Collegium's neuroscience portfolio and expand its market presence in the treatment of attention deficit hyperactivity disorder. Azstarys, a Schedule IV controlled substance, offers a novel delivery system for its active ingredients, potentially appealing to a broad patient base seeking effective ADHD management solutions.